Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 167

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 167
---
 will increase our legal
and financial compliance costs. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and
our ability to generate revenues, if any. The costs of advancing product candidates into each clinical phase tend to increase substantially
over the duration of the clinical development process. Therefore, the total costs to advance any of our product candidates to marketing
approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical
product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to
begin generating revenue from the commercialization of any products or achieve or maintain profitability.

The costs of advancing product
candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the
total costs to advance any of our product candidates to marketing approval in even a single jurisdiction will be substantial. Because
of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing
or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products
or achieve or maintain profitability.

Furthermore,
our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial
additional risks and uncertainties. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable
future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity
and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability
to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations,
or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve
profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve
or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially and adversely
affected.

Even if we are able to commercialize any
product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement
practices or healthcare reform initiatives that could harm our business.

The commercial success of
our product